GlassScriptPhysician profile
Aymin Delgado
NPI 1124098538
$44,645.47
in general payments reported to CMS, 2019-2025
24 companies · $5,227 in 2025
The $5,227 reported for 2025 was more than what 91% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $654 · 2021: $492 · 2022: $1,506 · 2023: $14K · 2024: $10K · 2025: $5,227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Travel and Lodging: $4,841 · Food and Beverage: $4,383 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,433.00 |
| Travel and Lodging | $4,840.78 |
| Food and Beverage | $4,382.84 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,320.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $14,774.28 | 2022-2025 | Livmarli |
| Alexion Pharmaceuticals, INC. | $13,707.56 | 2019-2022 | |
| Albireo Pharma, INC. | $8,118.02 | 2023 | Bylvay |
| Ipsen Biopharmaceuticals, INC | $4,229.85 | 2023-2025 | Bylvay, Iqirvo |
| Qol Medical, LLC | $788.41 | 2019-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $673.97 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $493.12 | 2020-2025 | Gattex, Eohilia |
| Genzyme Corporation | $473.43 | 2022-2025 | |
| Abbvie INC. | $413.94 | 2019-2022 | |
| Travere Therapeutics, INC. | $261.76 | 2019-2023 | Cholbam |
| Regeneron Healthcare Solutions, INC. | $198.49 | 2022-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $117.34 | 2020 | |
| Neuraxis, INC. | $80.74 | 2024 | |
| Celltrion USA INC. | $50.67 | 2025 | Vegzelma |
| Nestle Healthcare Nutrition INC. | $47.35 | 2021-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $39.58 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $29.50 | 2024 | Givlaari |
| Concordia Pharmaceuticals INC. | $24.02 | 2019 | |
| Capsovision, INC. | $22.72 | 2025 | Capsocam Plus |
| Amgen INC. | $21.40 | 2020 | |
| Fresenius Kabi USA, LLC | $20.96 | 2020 | |
| Phadia US INC. | $19.60 | 2023 | Immunocap |
| Aimmune Therapeutics, INC. | $19.49 | 2024 | |
| Sandoz INC. | $19.27 | 2025 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aymin Delgado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.